Proud to share our latest update highlighting encouraging initial safety and PK data with AX-0810 (cholestatic diseases), Development Candidate selection for AX-2402 (Rett syndrome) and AX-2911 (MASH), and strong momentum heading into 2026 as we advance our #Axiomer platform at ProQR.
January 8, 2026 at 1:11 PM
Proud to share our latest update highlighting encouraging initial safety and PK data with AX-0810 (cholestatic diseases), Development Candidate selection for AX-2402 (Rett syndrome) and AX-2911 (MASH), and strong momentum heading into 2026 as we advance our #Axiomer platform at ProQR.
#PRQR ProQR Announces Third Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
www.stocktitan.net
November 6, 2025 at 12:00 PM
#PRQR ProQR Announces Third Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
Join us in 60 mins for our virtual Investor and Analyst Event with ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen).
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing $PRQR
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing $PRQR
November 3, 2025 at 2:00 PM
Join us in 60 mins for our virtual Investor and Analyst Event with ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen).
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing $PRQR
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing $PRQR
Join us Nov 3 at 10:00 ET for our virtual Investor and Analyst Event with the ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen).
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing
October 27, 2025 at 1:37 PM
Join us Nov 3 at 10:00 ET for our virtual Investor and Analyst Event with the ProQR Management and KOL Prof. Henkjan Verkade, MD, PhD (UMC Groningen).
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing
Register for the event here: bit.ly/3Lb7GzE
#Axiomer #RNAEditing
October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
October 22, 2025 at 1:05 PM
October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture.
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
October 15, 2025 at 9:47 AM
David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture.
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
This would bypass the mutation, allowing a partially functional usherin to be produced. Exon skipping can be induced by antisense oligonucleotides (ASOs). Others have already shown feasibility in cultured cells, animal models & ProQR is currently testing an ASO in clinical trials (Ultevursen).
October 1, 2025 at 6:07 AM
This would bypass the mutation, allowing a partially functional usherin to be produced. Exon skipping can be induced by antisense oligonucleotides (ASOs). Others have already shown feasibility in cultured cells, animal models & ProQR is currently testing an ASO in clinical trials (Ultevursen).
Affinity Asset Advisors LLC Buys 459,512 Shares of ProQR Therapeutics N.V. $PRQR Affinity Asset Advisors LLC lifted its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report) by 16.3% durin...
#Banking #SEC #Filing #Articles
Origin | Interest | Match
#Banking #SEC #Filing #Articles
Origin | Interest | Match
Affinity Asset Advisors LLC Buys 459,512 Shares of ProQR Therapeutics N.V. $PRQR
Affinity Asset Advisors LLC lifted its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR – Free Report) by 16.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,284,512 shares of the biopharmaceutical company’s stock after acquiring an additional 459,512 shares during the period. Affinity Asset Advisors LLC’s […]
www.tickerreport.com
August 26, 2025 at 1:15 PM
Lemelinda pairs her passion for RNA biology with research, protocol development & biosafety support, while also fostering a strong community at ProQR through our Coffee & Collaboration Café.
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
August 26, 2025 at 9:36 AM
Lemelinda pairs her passion for RNA biology with research, protocol development & biosafety support, while also fostering a strong community at ProQR through our Coffee & Collaboration Café.
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
August 10, 2025 at 2:01 PM
#PRQR ProQR Announces Second Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
ProQR Announces Second Quarter 2025 Operating and Financial Results
ProQR Therapeutics (Nasdaq: PRQR) reported its Q2 2025 financial and operational results, highlighting significant progress in its RNA editing pipeline. The company has submitted a Clinical Trial Application for AX-0810, its lead program targeting NTCP for cholestatic diseases, with initial Phase 1 data expected in Q4 2025.ProQR maintains a strong financial position with €119.8 million in cash, providing runway into mid-2027. The company reported a net loss of €22.3 million for H1 2025. Notable developments include advancing AX-2402 for Rett Syndrome and achieving $2.0 million in milestone payments from its Eli Lilly collaboration, with potential for additional milestone income and expansion options.
www.stocktitan.net
August 7, 2025 at 11:00 AM
#PRQR ProQR Announces Second Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
As R&D Team Manager at ProQR, Lorenza drives scientific collaboration and project planning while also championing inclusivity as part of our DEI team.
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
July 22, 2025 at 8:45 AM
As R&D Team Manager at ProQR, Lorenza drives scientific collaboration and project planning while also championing inclusivity as part of our DEI team.
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
Fuchs Endothelial Corneal Dystrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen
Fuchs Endothelial Corneal Dystrophy Market To Reach New Heights In Growth By 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen | PressReleaseCC
www.pressreleasecc.com
July 7, 2025 at 5:13 PM
Fuchs Endothelial Corneal Dystrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen
Background:
ProQR Therapeutics, biotech company, focuses on RNA-based therapies for rare genetic disorders. Despite its innovative pipeline, the company has faced challenges, including a declining share price ($1.70 as of May 28, 2025, down 7.1% from May 29, 2024) and limited commercial progress.
ProQR Therapeutics, biotech company, focuses on RNA-based therapies for rare genetic disorders. Despite its innovative pipeline, the company has faced challenges, including a declining share price ($1.70 as of May 28, 2025, down 7.1% from May 29, 2024) and limited commercial progress.
July 1, 2025 at 2:53 PM
Background:
ProQR Therapeutics, biotech company, focuses on RNA-based therapies for rare genetic disorders. Despite its innovative pipeline, the company has faced challenges, including a declining share price ($1.70 as of May 28, 2025, down 7.1% from May 29, 2024) and limited commercial progress.
ProQR Therapeutics, biotech company, focuses on RNA-based therapies for rare genetic disorders. Despite its innovative pipeline, the company has faced challenges, including a declining share price ($1.70 as of May 28, 2025, down 7.1% from May 29, 2024) and limited commercial progress.
Van Herk Opposes $PRQR 's Reappointments
Van Herk Investments B.V., which holds over 10% of ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
Van Herk Investments B.V., which holds over 10% of ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
July 1, 2025 at 2:52 PM
Van Herk Opposes $PRQR 's Reappointments
Van Herk Investments B.V., which holds over 10% of ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
Van Herk Investments B.V., which holds over 10% of ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ:PRQR – Get Free Report)‘s stock had its “market outperform” rating reitera...
#Analyst #Articles #- #US #Economics
Origin | Interest | Match
#Analyst #Articles #- #US #Economics
Origin | Interest | Match
JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR)
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a note issued to investors on Friday,Benzinga reports. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. JMP Securities’ target price suggests a potential upside of 292.16% from the company’s current […]
reporter.am
June 29, 2025 at 6:07 AM
#PRQR ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
https://www.stocktitan.net/news/PRQR/pro-qr-announces-cta-submission-for-phase-1-study-of-ax-0810-pnt5sfasdwwa.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-cta-submission-for-phase-1-study-of-ax-0810-pnt5sfasdwwa.html
Breakthrough: ProQR's Revolutionary RNA Editing Platform Enters First Human Clinical Trial for Liver Disease Treatment
First-in-human trial of AX-0810 targets NTCP protein to combat liver diseases. See how this RNA editing breakthrough could transform treatment. Get trial timeline.
www.stocktitan.net
June 26, 2025 at 8:30 PM
#PRQR ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
https://www.stocktitan.net/news/PRQR/pro-qr-announces-cta-submission-for-phase-1-study-of-ax-0810-pnt5sfasdwwa.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-cta-submission-for-phase-1-study-of-ax-0810-pnt5sfasdwwa.html
At ProQR, we’re proud to foster a culture where everyone feels safe to be themselves. To celebrate #Pride, our DEI team hosted a rainbow themed coffee & collaboration event with multicoloured cakes and a movie night featuring an LGBTQIA+ film and discussion.
#Inclusivity #RNAEditing #Axiomer
#Inclusivity #RNAEditing #Axiomer
June 12, 2025 at 7:33 AM
At ProQR, we’re proud to foster a culture where everyone feels safe to be themselves. To celebrate #Pride, our DEI team hosted a rainbow themed coffee & collaboration event with multicoloured cakes and a movie night featuring an LGBTQIA+ film and discussion.
#Inclusivity #RNAEditing #Axiomer
#Inclusivity #RNAEditing #Axiomer
Van Herk Rejects #ProQR Leadership
Van Herk Investments B.V., which holds over 10% of #ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
Van Herk Investments B.V., which holds over 10% of #ProQR, issued a letter on May 23, 2025, opposing the reappointments of CEO Daniel de Boer and Chairman James Shannon due to persistent underperformance, strategic missteps, and governance lapses.
June 10, 2025 at 7:40 PM
#ProQR votes are out. deBoer (86.3%) + Shannon (80.7%) re-appointed as Directors. Should encourage corp governance discussion.
Only 78.5% of votes cast were in favor of authorizing Board to issue shares. Not sure the 'no' are aware that we are in the biotech business?
www.sec.gov/Archives/edg...
Only 78.5% of votes cast were in favor of authorizing Board to issue shares. Not sure the 'no' are aware that we are in the biotech business?
www.sec.gov/Archives/edg...
www.sec.gov
June 3, 2025 at 8:37 PM
#ProQR votes are out. deBoer (86.3%) + Shannon (80.7%) re-appointed as Directors. Should encourage corp governance discussion.
Only 78.5% of votes cast were in favor of authorizing Board to issue shares. Not sure the 'no' are aware that we are in the biotech business?
www.sec.gov/Archives/edg...
Only 78.5% of votes cast were in favor of authorizing Board to issue shares. Not sure the 'no' are aware that we are in the biotech business?
www.sec.gov/Archives/edg...
No, unfortunately. We should see the voting results soon. No filings yet. The message should be clear: more urgency, plus I want to see the NTCP preclinical package when #ProQR announce CTA.
June 3, 2025 at 4:13 PM
No, unfortunately. We should see the voting results soon. No filings yet. The message should be clear: more urgency, plus I want to see the NTCP preclinical package when #ProQR announce CTA.
#ProQR
They changed delivery, so if the data gains by leaps and bounds, director term limits can take a backseat.
What I dont like is the Lily blackout even when there is progress payment of $1m in 1Q25.
They changed delivery, so if the data gains by leaps and bounds, director term limits can take a backseat.
What I dont like is the Lily blackout even when there is progress payment of $1m in 1Q25.
May 30, 2025 at 2:29 PM
#ProQR
They changed delivery, so if the data gains by leaps and bounds, director term limits can take a backseat.
What I dont like is the Lily blackout even when there is progress payment of $1m in 1Q25.
They changed delivery, so if the data gains by leaps and bounds, director term limits can take a backseat.
What I dont like is the Lily blackout even when there is progress payment of $1m in 1Q25.